{"product_id":"cardiovascular-diseases-isbn-9780470915370","title":"Cardiovascular Diseases","description":"Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases.\u003cbr\u003e \u003cbr\u003e •    Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases\u003cbr\u003e •    Facilitates understanding of drug action and mechanism by covering physiology \/ pathophysiology and pharmacology\u003cbr\u003e •    Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases\u003cbr\u003e •    Uses case presentations and study questions to enhance understanding of the material\u003cbr\u003e •    Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues \u003cp\u003e\u003cb\u003ePREFACE xix\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eLIST OF ABBREVIATIONS xxii\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUNIT I GENERAL INTRODUCTION 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction to Cardiovascular Diseases 3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1.1 Overview 3\u003c\/p\u003e \u003cp\u003e1.2 Definition of Cardiovascular Diseases 3\u003c\/p\u003e \u003cp\u003e1.3 Classification of Cardiovascular Diseases 3\u003c\/p\u003e \u003cp\u003e1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases 5\u003c\/p\u003e \u003cp\u003e1.5 Risk Factors of Cardiovascular Diseases 9\u003c\/p\u003e \u003cp\u003e1.6 Prevention and Control of Cardiovascular Diseases 10\u003c\/p\u003e \u003cp\u003e1.7 Cardiovascular Risk Prediction and Evidence]Based Treatments 15\u003c\/p\u003e \u003cp\u003e1.8 Summary of Chapter Key Points 18\u003c\/p\u003e \u003cp\u003e1.9 Self-Assessment Questions 18\u003c\/p\u003e \u003cp\u003eReferences 19\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Introduction to Principles of Pharmacology 21\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2.1 Overview 21\u003c\/p\u003e \u003cp\u003e2.2 Definitions and History 21\u003c\/p\u003e \u003cp\u003e2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology 24\u003c\/p\u003e \u003cp\u003e2.4 Principles of Drug Discovery, Development, and Regulation 31\u003c\/p\u003e \u003cp\u003e2.5 Pharmacology Subspecialties 32\u003c\/p\u003e \u003cp\u003e2.6 Introduction to Cardiovascular Pharmacology 32\u003c\/p\u003e \u003cp\u003e2.7 Summary of Chapter Key Points 38\u003c\/p\u003e \u003cp\u003e2.8 Self]Assessment Questions 39\u003c\/p\u003e \u003cp\u003eReferences 40\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUNIT II DYSLIPIDEMIAS 43\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Overview of Dyslipidemias and Drug Therapy 45\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 45\u003c\/p\u003e \u003cp\u003e3.2 Lipoprotein Metabolism 45\u003c\/p\u003e \u003cp\u003e3.3 Dyslipidemias and Genetic Lipoprotein Disorders 51\u003c\/p\u003e \u003cp\u003e3.4 Mechanistically Based Drug Therapy of Dyslipidemias 51\u003c\/p\u003e \u003cp\u003e3.5 Summary of Chapter Key Points 53\u003c\/p\u003e \u003cp\u003e3.6 Self]Assessment Questions 54\u003c\/p\u003e \u003cp\u003eReferences 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Drugs for Dyslipidemias 56\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4.1 Overview 56\u003c\/p\u003e \u003cp\u003e4.2 Statins 56\u003c\/p\u003e \u003cp\u003e4.3 Bile Acid Sequestrants 64\u003c\/p\u003e \u003cp\u003e4.4 Cholesterol Absorption Inhibitors 69\u003c\/p\u003e \u003cp\u003e4.5 Fibrates 72\u003c\/p\u003e \u003cp\u003e4.6 Niacin 75\u003c\/p\u003e \u003cp\u003e4.7 New Drugs for HoFH 80\u003c\/p\u003e \u003cp\u003e4.8 Phytosterols and Phytostanols 83\u003c\/p\u003e \u003cp\u003e4.9 Omega]3 Fatty Acids 86\u003c\/p\u003e \u003cp\u003e4.10 Emerging Therapeutic Modalities for Dyslipidemias 88\u003c\/p\u003e \u003cp\u003e4.11 Summary of Chapter Key Points 93\u003c\/p\u003e \u003cp\u003e4.12 Self-Assessment Questions 93\u003c\/p\u003e \u003cp\u003eReferences 95\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Management of Dyslipidemias: Principles and Guidelines 99\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5.1 Overview 99\u003c\/p\u003e \u003cp\u003e5.2 General Principles of the Management of Dyslipidemias 99\u003c\/p\u003e \u003cp\u003e5.3 Current Evidence]Based Guidelines on the Management of Dyslipidemias 102\u003c\/p\u003e \u003cp\u003e5.4 Summary of Chapter Key Points 113\u003c\/p\u003e \u003cp\u003e5.5 Self]Assessment Questions 113\u003c\/p\u003e \u003cp\u003eReferences 114\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUNIT III HYPERTENSION AND MULTITASKING CARDIOVASCULAR DRUGS 117\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Overview of Hypertension and Drug Therapy 119\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 119\u003c\/p\u003e \u003cp\u003e6.2 Definitions, Classifications, and Epidemiology of Hypertension 119\u003c\/p\u003e \u003cp\u003e6.3 Pathophysiology of Hypertension 121\u003c\/p\u003e \u003cp\u003e6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview 123\u003c\/p\u003e \u003cp\u003e6.5 Summary of Chapter Key Points 123\u003c\/p\u003e \u003cp\u003e6.6 Self]Assessment Questions 125\u003c\/p\u003e \u003cp\u003eReferences 125\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Diuretics 127\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7.1 Overview 127\u003c\/p\u003e \u003cp\u003e7.2 Volume Regulation and Drug Targeting 127\u003c\/p\u003e \u003cp\u003e7.3 Thiazide and Thiazide]Type Diuretics 129\u003c\/p\u003e \u003cp\u003e7.4 Loop Diuretics 134\u003c\/p\u003e \u003cp\u003e7.5 Potassium]Sparing Diuretics 138\u003c\/p\u003e \u003cp\u003e7.6 Other Diuretics 142\u003c\/p\u003e \u003cp\u003e7.7 Summary of Chapter Key Points 143\u003c\/p\u003e \u003cp\u003e7.8 Self]Assessment Questions 143\u003c\/p\u003e \u003cp\u003eReferences 144\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Sympatholytics 147\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8.1 Overview 147\u003c\/p\u003e \u003cp\u003e8.2 Sympathetic Nervous System and Drug Targeting 147\u003c\/p\u003e \u003cp\u003e8.3 α]Adrenergic Receptor Antagonists 150\u003c\/p\u003e \u003cp\u003e8.4 β]Adrenergic Receptor Antagonists 150\u003c\/p\u003e \u003cp\u003e8.5 Centrally Acting Sympatholytics 157\u003c\/p\u003e \u003cp\u003e8.6 Summary of Chapter Key Points 158\u003c\/p\u003e \u003cp\u003e8.7 Self]Assessment Questions 159\u003c\/p\u003e \u003cp\u003eReferences 159\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Inhibitors of the Renin–Angiotensin–Aldosterone System 161\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9.1 Overview 161\u003c\/p\u003e \u003cp\u003e9.2 The RAAS and Drug Targeting 161\u003c\/p\u003e \u003cp\u003e9.3 Direct Renin Inhibitors 162\u003c\/p\u003e \u003cp\u003e9.4 ACE Inhibitors 166\u003c\/p\u003e \u003cp\u003e9.5 ARBs 174\u003c\/p\u003e \u003cp\u003e9.6 Comparative Pharmacology of Direct Renin Inhibitors, ACE Inhibitors, and ARBs 179\u003c\/p\u003e \u003cp\u003e9.7 Summary of Chapter Key Points 181\u003c\/p\u003e \u003cp\u003e9.8 Self-Assessment Questions 181\u003c\/p\u003e \u003cp\u003eReferences 182\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Calcium Channel Blockers 185\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e10.1 Overview 185\u003c\/p\u003e \u003cp\u003e10.2 Calcium Channels and Drug Targeting 185\u003c\/p\u003e \u003cp\u003e10.3 L-TYPE CCBs 186\u003c\/p\u003e \u003cp\u003e10.4 Summary of Chapter Key Points 192\u003c\/p\u003e \u003cp\u003e10.5 Self-Assessment Questions 192\u003c\/p\u003e \u003cp\u003eReferences 193\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Nitrates and Other Vasodilators 194\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11.1 Overview 194\u003c\/p\u003e \u003cp\u003e11.2 Drug Class and Drug Targeting 194\u003c\/p\u003e \u003cp\u003e11.3 Organic Nitrates and Sodium Nitroprusside (Nitric Oxide]Releasing Vasodilators) 196\u003c\/p\u003e \u003cp\u003e11.4 ET Receptor Antagonists 201\u003c\/p\u003e \u003cp\u003e11.5 Phosphodiesterase 5 Inhibitors 204\u003c\/p\u003e \u003cp\u003e11.6 sGC Stimulators 207\u003c\/p\u003e \u003cp\u003e11.7 K+ATP Channel Openers 209\u003c\/p\u003e \u003cp\u003e11.8 Other Vasodilators 210\u003c\/p\u003e \u003cp\u003e11.9 Summary of Chapter Key Points 212\u003c\/p\u003e \u003cp\u003e11.10 Self-Assessment Questions 212\u003c\/p\u003e \u003cp\u003eReferences 213\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Management of Hypertension: Principles and Guidelines 215\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12.1 Overview 215\u003c\/p\u003e \u003cp\u003e12.2 Introduction to Current Guidelines for the Management of Systemic Hypertension 215\u003c\/p\u003e \u003cp\u003e12.3 Key Recommendations of Major Guidelines for the Management of Systemic Hypertension 217\u003c\/p\u003e \u003cp\u003e12.4 Lifestyle Modifications for the Management of Systemic Hypertension 221\u003c\/p\u003e \u003cp\u003e12.5 Drug Therapy of Systemic Hypertension 223\u003c\/p\u003e \u003cp\u003e12.6 Drug Therapy of Prehypertension 234\u003c\/p\u003e \u003cp\u003e12.7 Drug Therapy of Pulmonary Hypertension 235\u003c\/p\u003e \u003cp\u003e12.8 Summary of Chapter Key Points 237\u003c\/p\u003e \u003cp\u003e12.9 Self-Assessment Questions 238\u003c\/p\u003e \u003cp\u003eReferences 239\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUNIT IV ISCHEMIC HEART DISEASE: STABLE ISCHEMIC HEART DISEASE 243\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Overview of Ischemic Heart Disease, Stable Angina, and Drug Therapy 245\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 245\u003c\/p\u003e \u003cp\u003e13.2 Classification, Epidemiology, and Pathophysiology 245\u003c\/p\u003e \u003cp\u003e13.3 Stable Angina and Drug Targeting 250\u003c\/p\u003e \u003cp\u003e13.4 Summary of Chapter Key Points 252\u003c\/p\u003e \u003cp\u003e13.5 Self-Assessment Questions 252\u003c\/p\u003e \u003cp\u003eReferences 253\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Drugs for Stable Angina 254\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14.1 Overview 254\u003c\/p\u003e \u003cp\u003e14.2 β-Blockers for Treating Stable Angina 254\u003c\/p\u003e \u003cp\u003e14.3 CCBs for Treating Stable Angina 255\u003c\/p\u003e \u003cp\u003e14.4 Organic Nitrate for Treating Stable Angina 255\u003c\/p\u003e \u003cp\u003e14.5 New Antianginal Drugs: Ranolazine 255\u003c\/p\u003e \u003cp\u003e14.6 Other New and Emerging Drugs 258\u003c\/p\u003e \u003cp\u003e14.7 Summary of Chapter Key Points 259\u003c\/p\u003e \u003cp\u003e14.8 Self-Assessment Questions 259\u003c\/p\u003e \u003cp\u003eReferences 260\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Management of Stable Angina\/Stable Ischemic Heart Disease: Principles and Guidelines 262\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e15.1 Overview 262\u003c\/p\u003e \u003cp\u003e15.2 Introduction to Current Guidelines on Management of Stable Angina\/SIHD 262\u003c\/p\u003e \u003cp\u003e15.3 General Principles of Management of Stable Angina\/SIHD 265\u003c\/p\u003e \u003cp\u003e15.4 Current Guideline Recommendations on Stable Angina\/SIHD Management 266\u003c\/p\u003e \u003cp\u003e15.5 Management of Special Types of Stable Angina 271\u003c\/p\u003e \u003cp\u003e15.6 Summary of Chapter Key Points 273\u003c\/p\u003e \u003cp\u003e15.7 Self-Assessment Questions 273\u003c\/p\u003e \u003cp\u003eReferences 273\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUNIT V ISCHEMIC HEART DISEASE: ACUTE CORONARY SYNDROMES 275\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Overview of Acute Coronary Syndromes and Drug Therapy 277\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 277\u003c\/p\u003e \u003cp\u003e16.2 Definitions and General Considerations 277\u003c\/p\u003e \u003cp\u003e16.3 Pathophysiology and Drug Targeting 278\u003c\/p\u003e \u003cp\u003e16.4 Summary of Chapter Key Points 280\u003c\/p\u003e \u003cp\u003e16.5 Self-Assessment Questions 281\u003c\/p\u003e \u003cp\u003eReferences 281\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Anticoagulants, Platelet Inhibitors, and Thrombolytic Agents 283\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e17.1 Overview 283\u003c\/p\u003e \u003cp\u003e17.2 Hemostasis 283\u003c\/p\u003e \u003cp\u003e17.3 Anticoagulants 285\u003c\/p\u003e \u003cp\u003e17.4 Platelet Inhibitors 295\u003c\/p\u003e \u003cp\u003e17.5 Thrombolytic Agents 304\u003c\/p\u003e \u003cp\u003e17.6 Summary of Chapter Key Points 307\u003c\/p\u003e \u003cp\u003e17.7 Self-Assessment Questions 307\u003c\/p\u003e \u003cp\u003eReferences 308\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Management of Unstable Angina and Non-\u003c\/b\u003e\u003cb\u003eST-\u003c\/b\u003e\u003cb\u003eElevation Myocardial Infarction: Principles and Guidelines 310\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18.1 Overview 310\u003c\/p\u003e \u003cp\u003e18.2 Introduction to Evidence-Based Guidelines 310\u003c\/p\u003e \u003cp\u003e18.3 General Principles of Management of UA\/NSTEMI 311\u003c\/p\u003e \u003cp\u003e18.4 Guideline-Based Recommendations on the Management of UA\/NSTEMI 311\u003c\/p\u003e \u003cp\u003e18.5 Summary of Chapter Key Points 324\u003c\/p\u003e \u003cp\u003e18.6 Self-Assessment Questions 325\u003c\/p\u003e \u003cp\u003eReferences 325\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Management of ST-\u003c\/b\u003e\u003cb\u003eElevation Myocardial Infarction: Principles and Guidelines 327\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19.1 Overview 327\u003c\/p\u003e \u003cp\u003e19.2 Definition and Epidemiology 327\u003c\/p\u003e \u003cp\u003e19.3 Introduction to Recent Guidelines on the Management of STEMI 328\u003c\/p\u003e \u003cp\u003e19.4 Principles and Guideline Recommendations for the Management of STEMI 329\u003c\/p\u003e \u003cp\u003e19.5 Summary of Chapter Key Points 339\u003c\/p\u003e \u003cp\u003e19.6 Self-Assessment Questions 340\u003c\/p\u003e \u003cp\u003eReferences 340\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUNIT VI HEART FAILURE 343\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Overview of Heart Failure and Drug Therapy 345\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20.1 Introduction 345\u003c\/p\u003e \u003cp\u003e20.2 Definition, Classification, and Epidemiology 345\u003c\/p\u003e \u003cp\u003e20.3 Pathophysiology and Drug Targeting 348\u003c\/p\u003e \u003cp\u003e20.4 Summary of Chapter Key Points 349\u003c\/p\u003e \u003cp\u003e20.5 Self-Assessment Questions 350\u003c\/p\u003e \u003cp\u003eReferences 350\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Drugs for Heart Failure 352\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e21.1 Overview 352\u003c\/p\u003e \u003cp\u003e21.2 Diuretics for Heart Failure 352\u003c\/p\u003e \u003cp\u003e21.3 β-Blockers for HF 352\u003c\/p\u003e \u003cp\u003e21.4 Inhibitors of the RAAS for HF 353\u003c\/p\u003e \u003cp\u003e21.5 Vasodilators for HF 354\u003c\/p\u003e \u003cp\u003e21.6 Positive Inotropic Agents for HF 354\u003c\/p\u003e \u003cp\u003e21.7 Emerging Drugs for HF 359\u003c\/p\u003e \u003cp\u003e21.8 Summary of Chapter Key Points 360\u003c\/p\u003e \u003cp\u003e21.9 Self-Assessment Questions 360\u003c\/p\u003e \u003cp\u003eReferences 361\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Management of Heart Failure: Principles and Guidelines 364\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22.1 Overview 364\u003c\/p\u003e \u003cp\u003e22.2 Management of Hf-REF 364\u003c\/p\u003e \u003cp\u003e22.3 Management of HF-PEF 367\u003c\/p\u003e \u003cp\u003e22.4 Management of Acute Heart Failure Syndromes 368\u003c\/p\u003e \u003cp\u003e22.5 Summary of Chapter Key Points 372\u003c\/p\u003e \u003cp\u003e22.6 Self-Assessment Questions 373\u003c\/p\u003e \u003cp\u003eReferences 374\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUNIT Vii CARDIAC ARRHYTHMIAS 375\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Overview of Cardiac Arrhythmias and Drug Therapy 377\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e23.1 Introduction 377\u003c\/p\u003e \u003cp\u003e23.2 Definition, Classification, and Epidemiology 377\u003c\/p\u003e \u003cp\u003e23.3 Pathophysiology and Drug Targeting 380\u003c\/p\u003e \u003cp\u003e23.4 Summary of Chapter Key Points 388\u003c\/p\u003e \u003cp\u003e23.5 Self-Assessment Questions 389\u003c\/p\u003e \u003cp\u003eReferences 390\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Drugs for Cardiac Arrhythmias 391\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24.1 Overview 391\u003c\/p\u003e \u003cp\u003e24.2 Classification of Antiarrhythmic Drugs 391\u003c\/p\u003e \u003cp\u003e24.3 Class I Antiarrhythmic Drugs 392\u003c\/p\u003e \u003cp\u003e24.4 Class II Antiarrhythmic Drugs 398\u003c\/p\u003e \u003cp\u003e24.5 Class III Antiarrhythmic Drugs 399\u003c\/p\u003e \u003cp\u003e24.6 Class IV Antiarrhythmic Drugs 404\u003c\/p\u003e \u003cp\u003e24.7 Other Antiarrhythmic Drugs 406\u003c\/p\u003e \u003cp\u003e24.8 Summary of Chapter Key Points 408\u003c\/p\u003e \u003cp\u003e24.9 Self-Assessment Questions 409\u003c\/p\u003e \u003cp\u003eReferences 410\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Management of Cardiac Arrhythmias: Principles and Guidelines 411\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e25.1 Overview 411\u003c\/p\u003e \u003cp\u003e25.2 General Principles of Management 411\u003c\/p\u003e \u003cp\u003e25.3 Management of Supraventricular Arrhythmias 411\u003c\/p\u003e \u003cp\u003e25.4 Management of Ventricular Arrhythmias 414\u003c\/p\u003e \u003cp\u003e25.5 Summary of Chapter Key Points 421\u003c\/p\u003e \u003cp\u003e25.6 Self-Assessment Questions 423\u003c\/p\u003e \u003cp\u003eReferences 424\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUNIT Viii ISCHEMIC STROKE 427\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26 Overview of Ischemic Stroke and Drug Therapy 429\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e26.1 Introduction 429\u003c\/p\u003e \u003cp\u003e26.2 Definition and Classification of Cerebrovascular Diseases 429\u003c\/p\u003e \u003cp\u003e26.3 Definition and Classification of Stroke 429\u003c\/p\u003e \u003cp\u003e26.4 Epidemiology of Stroke 430\u003c\/p\u003e \u003cp\u003e26.5 Risk Factors of Stroke 432\u003c\/p\u003e \u003cp\u003e26.6 Pathophysiology of Ischemic Stroke and Drug Targeting 432\u003c\/p\u003e \u003cp\u003e26.7 Summary of Chapter Key Points 434\u003c\/p\u003e \u003cp\u003e26.8 Self]Assessment Questions 434\u003c\/p\u003e \u003cp\u003eReferences 435\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27 Drugs for Ischemic Stroke 436\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27.1 Overview 436\u003c\/p\u003e \u003cp\u003e27.2 Drugs for Primary Prevention of Ischemic Stroke 436\u003c\/p\u003e \u003cp\u003e27.3 Drugs for Early Treatment of Acute Ischemic Stroke 438\u003c\/p\u003e \u003cp\u003e27.4 Drugs for Neuroprotection 439\u003c\/p\u003e \u003cp\u003e27.5 Drugs for Secondary Prevention of Ischemic Stroke 441\u003c\/p\u003e \u003cp\u003e27.6 Stem Cell Therapy for Neurorepair 442\u003c\/p\u003e \u003cp\u003e27.7 Summary of Chapter Key Points 442\u003c\/p\u003e \u003cp\u003e27.8 Self-Assessment Questions 443\u003c\/p\u003e \u003cp\u003eReferences 444\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28 Management of Ischemic Stroke: Principles and Guidelines 447\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e28.1 Overview 447\u003c\/p\u003e \u003cp\u003e28.2 Introduction to Stroke Systems of Care 447\u003c\/p\u003e \u003cp\u003e28.3 Current AHA\/ASA Guidelines on Early Management of Acute Ischemic Stroke 449\u003c\/p\u003e \u003cp\u003e28.4 Summary of Chapter Key Points 450\u003c\/p\u003e \u003cp\u003e28.5 Self-Assessment Questions 455\u003c\/p\u003e \u003cp\u003eReferences 456\u003c\/p\u003e \u003cp\u003e\u003cb\u003eINDEX 457\u003c\/b\u003e\u003c\/p\u003e \u003cb\u003eY. Robert Li\u003c\/b\u003e is Professor and Founding Chair of the Department of Pharmacology and Assistant Dean for Biomedical Research at Campbell University and holds Adjunct Professor appointments at Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, Virginia-Maryland Regional College of Veterinary Medicine, and University of North Carolina at Greensboro. He is an author of over 110 peer-reviewed publications, three monographs, and numerous book chapters and serves on the editorial boards of several leading journals. Dr. Li has over 20 years of teaching experience in the areas of biomedical sciences, free radical biology, toxicology, pharmacology, and therapeutics.  Even though there has been improvement in treatment and significant reduction in mortality rate, cardiovascular disease remains one of the leading causes of death around the world. Drug therapy continues to rank high as a way to manage heart disease – making cardiovascular pharmacology a key part of medical education and drug development research.\u003cbr\u003e \u003cbr\u003e This book addresses the needs of these students and researchers by systematically integrating essentials, advances, and clinical correlations for cardiovascular drugs. The author, who has over two decades of experience teaching this topic, covers both the fundamentals and most recent advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. In addition, the text presents evidence-based pharmacotherapeutics in the management of common cardiovascular diseases and conditions that include dyslipidemias, hypertension, ischemic heart disease, heart failure, cardiac arrhythmias, and ischemic stroke.\u003cbr\u003e \u003cbr\u003e Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases.\u003cbr\u003e \u003cbr\u003e •    Blends basic and clinical sciences needed to effectively understand and treat cardiovascular diseases\u003cbr\u003e •    Facilitates understanding of drug action and mechanism by covering physiology \/ pathophysiology and pharmacology\u003cbr\u003e •    Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases\u003cbr\u003e •    Uses case presentations and study questions to enhance understanding of the material\u003cbr\u003e •    Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988887257317,"sku":"NP9780470915370","price":114.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470915370.jpg?v=1761781924","url":"https:\/\/k12savings.com\/es\/products\/cardiovascular-diseases-isbn-9780470915370","provider":"K12savings","version":"1.0","type":"link"}